BPC-157 · research summary

BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.

International journal of molecular sciences · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Critical review of preclinical rodent studies
“This critical review evaluates the preclinical evidence for BPC 157 in rodent IRI and related reperfusion-associated vascular injury models”

Sample size

Six primary in vivo rodent studies
“Six primary in vivo rodent studies met the criteria for the core IRI/reperfusion evidence synthesis [6,13,14,15,16,17].”

Duration

Searches performed up to 24 June 2026
“Searches were performed up to 24 June 2026 across PubMed/MEDLINE, Web of Science Core Collection, Scopus, PMC, publisher/DOI metadata, ClinicalTrials.gov, FDA materials, and WADA materials.”

Reported findings

BPC 157 administration was associated with attenuation of oxidative injury and modulation of NO-related vascular responses.
“Across the available rodent literature, BPC 157 administration has been associated with attenuation of oxidative injury, modulation of NO-related vascular responses, reductions in inflammatory and apoptotic markers, and changes in VEGF/VEGFR2–Akt–eNOS-related signaling.”
Organ-specific findings included biochemical, molecular, and histological protection in lower-extremity skeletal-muscle IRI and attenuation of distant-organ injury.
“Organ-specific findings include biochemical, molecular, and histological protection in lower-extremity skeletal-muscle IRI; attenuation of distant-organ injury following limb IRI; neuronal and functional effects in hippocampal IRI; vascular and tissue-protective responses in intestinal/colonic IRI; and hemodynamic and histological effects in hepatic Pringle-maneuver IRI.”
Current evidence supports BPC 157 as a hypothesis-generating investigational candidate rather than an established therapy.
“Current evidence therefore supports BPC 157 as a hypothesis-generating investigational candidate for further preclinical IRI research rather than as an established therapy.”

Source: PubMed 42794771 · DOI 10.3390/ijms27188344 · all study summaries

Reported findings

BPC 157 administration was associated with attenuation of oxidative injury and modulation of NO-related vascular responses.

“Across the available rodent literature, BPC 157 administration has been associated with attenuation of oxidative injury, modulation of NO-related vascular responses, reductions in inflammatory and apoptotic markers, and changes in VEGF/VEGFR2–Akt–eNOS-related signaling.”

Organ-specific findings included biochemical, molecular, and histological protection in lower-extremity skeletal-muscle IRI and attenuation of distant-organ injury.

“Organ-specific findings include biochemical, molecular, and histological protection in lower-extremity skeletal-muscle IRI; attenuation of distant-organ injury following limb IRI; neuronal and functional effects in hippocampal IRI; vascular and tissue-protective responses in intestinal/colonic IRI; and hemodynamic and histological effects in hepatic Pringle-maneuver IRI.”

Current evidence supports BPC 157 as a hypothesis-generating investigational candidate rather than an established therapy.

“Current evidence therefore supports BPC 157 as a hypothesis-generating investigational candidate for further preclinical IRI research rather than as an established therapy.”